肽RmS-17免疫抗微小扇头蜱的首次评价:一项牛群对照试验
该对照试验将15头牛分为pRmS-17组、Bm86抗原组和生理盐水/佐剂组,每组5头,于第0、4、6周各免疫100 μg/剂,第7周以5000只微小扇头蜱幼虫攻击感染。pRmS-17组成年雌蜱数减少40%、产卵减少28%、幼虫孵化减少31%(P < 0.05),总体效力70%,Bm86组总体效力67%。
要点
- pRmS-17免疫使成年雌蜱数减少40%、产卵减少28%、幼虫孵化减少31%(P < 0.05),总体效力70%。
- Bm86抗原组总体效力为67%。
- 抗体水平与蜱数量减少呈负相关,提示pRmS-17效果源于牛的抗体反应。
核心结论
- 结果表明pRmS-17抗原具有诱导免疫保护的潜力,是下一代蜱疫苗的有前景候选抗原,并支持进一步研究以验证其在不同生产系统中的实用性。
研究设计与样本
- 在牛中开展的对照试验,15头Bos taurus犊牛分为三组(每组n=5):组1为pRmS-17,组2为Bm86抗原(阳性对照),组3为生理盐水/佐剂(对照)。
- 牛于第0、4、6周接受三次100 μg/剂免疫,第7周以5000只微小扇头蜱幼虫进行攻击感染。
- 采用ELISA检测IgG抗体水平并用Western blot确认,同时评估微小扇头蜱的生殖性能。
主要发现
- pRmS-17免疫组对蜱生物学参数有显著影响:成年雌蜱数减少40%、产卵减少28%、幼虫孵化减少31%(P < 0.05),总体效力70%。
- Bm86抗原组总体效力为67%。
- pRmS-17免疫犊牛产生强体液免疫应答,特征为高IgG水平,Western blot确认了该肽的免疫原性。
- 抗体水平与采集蜱数量减少之间呈负相关,表明pRmS-17的效果是牛抗体反应的结果。
- Bm86免疫犊牛的结果与既往报道相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论支持进一步研究以验证pRmS-17在不同生产系统中的实用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rhipicephalus microplus is the most significant tick affecting cattle globally. Chemical acaricides are the main control method, but improper use has led to resistant tick strains. In this context, anti-tick vaccines offer a sustainable alternative for integrated tick management, helping to reduce tick infestation in cattle production. Therefore, it is important to evaluate promising antigens for developing anti-tick vaccines. This study evaluated the efficacy of the peptide RmS-17 on R. microplus tick biology through a controlled trial in cattle. Fifteen Bos taurus calves were distributed into three experimental groups (n = 5): Group 1: pRmS-17, Group 2: Bm86 antigen (control +), and Group 3: saline/adjuvant (control). Cattle received three immunizations of 100 μg/dose at weeks 0, 4, and 6, followed by a challenge infestation with 5000 R. microplus larvae at week 7. IgG antibody levels were measured using ELISA and confirmed with Western blot; also, the reproductive performance of R. microplus was assessed. Animals immunized with the pRmS-17 showed a significant effect on tick biological parameters, with reductions in adult female tick numbers (40 %), oviposition (28 %), and larvae hatching (31 %) (P < 0.05), resulting in an overall efficacy of 70 %. The Bm86 antigen showed an overall efficacy of 67 %. The pRmS-17-immunized calves developed a strong humoral immune response, characterized by high IgG levels, and Western blot confirmed the immunogenicity of the peptide. Additionally, the negative correlation between antibody levels and reduction in the number of ticks collected indicated that the effect of pRmS-17 was a result of the antibody response in cattle. Bm86-immunized calves had results similar to previous reports. In conclusion, the results indicate that the pRmS-17 antigen has the potential to induce immune protection, making it a promising candidate for a next-generation tick vaccine, and support further studies to validate its usefulness under diverse production systems.
引用
- Lagunes-Quintanilla R, Castañeda-Arriola R, Camas-Pereyra R, et al. First evaluation of the peptide RmS-17 immunization against Rhipicephalus microplus: a controlled trial in cattle. Vaccine. 2025. PMID: 41344035. doi:10.1016/j.vaccine.2025.128047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。